AXD2.F Heron Therapeutics Inc

Healthcare Biotechnology Frankfurt Exchange
0.3352 EUR
Close of Nov 11, 2026
0.2462 1.29
Market cap
EUR 63.8M
P/E
-
P/B
18.23x
ROE
-504.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AXD2.F undervalued?

Graham number

The Graham number of Heron Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Heron Therapeutics Inc fundamental analysis

No fundamental analysis for Heron Therapeutics Inc yet.

Heron Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of…

Full company profile